Wellcome Trust to buy Millennium Dome?
The UK medical charity, the Wellcome Trust, is reported to be planninga L300 million ($420.2 million) bid to turn the Millennium Dome, based on the outskirts of London, into a biomedical research center. The Sunday Telegraph newspaper claimed that the trust intends to build laboratories inside the Dome for research purposes and may also set up public exhibitions displaying its work.
However, there was a tight-lipped response from the potential buyers, the only one being a statement saying that "the Wellcome Trust's investment portfolio is constantly under review and at any one time several opportunities may be under consideration."
Dome - millstone round govt's neck
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze